[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-disease-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-disease-chronic":482},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,39,71,104,134,160,184,206,229,251,272,294,323,347,377,397,422,452],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100556954",false,"NCT06531824","EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)","A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease","Key Inclusion Criteria:\n\n* Evidence of chronic kidney disease (CKD) at risk of kidney disease progression is defined on the basis of local laboratory results recorded at least 3 months before and at the time of the Screening visit, and requires:\n\n  1. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR ≥20 \\\u003C45 mL\u002Fmin\u002F1.73m²; or\n  2. CKD-EPI eGFR ≥45 \\\u003C90 mL\u002Fmin\u002F1.73m² with urine albumin-to-creatinine ratio (uACR) ≥200 mg\u002Fg (or protein-to-creatinine ratio ≥300 mg\u002Fg).\n* Neither requires an Aldosterone Synthase inhibitor (ASi) or Mineralocorticoid Receptor Antagonist (MRA), nor that such treatment is definitely inappropriate.\n\nKey Exclusion Criteria:\n\n* Blood potassium of \\>5.2 mmol\u002FL at screening visit\n* Blood Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \\>3x Upper Limit of Normal (ULN) at Screening visit\n* Known liver cirrhosis\n* On dialysis, functioning kidney transplant, or scheduled living donor transplant\n* Treated with new immunosuppression therapy for new (or relapse\u002Fflare of pre-existing) kidney disease within the last 60 days\n* Receiving more than one Renin-Angiotensin System (RAS) inhibitor (i.e. on dual therapy with two of an Angiotensin-Converting Enzyme inhibitor (ACEi), Angiotensin Receptor Blocker (ARB) or direct renin inhibitor)\n* Currently treated with an Mineralocorticoid Receptor Antagonist (MRA) (e.g. spironolactone, eplerenone, finerenone)\n* Currently treated with systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.","ALL","18 Years",{"count":18,"type":19},11000,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart disease.\n\nAfter a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study.\n\nThe doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 4 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.",[25],"Kidney Disease, Chronic","RECRUITING","2026-06-23",{"date":29,"type":30},"2026-06-24","ACTUAL",{"date":32,"type":30},"2024-08-30",{"date":34,"type":19},"2028-08-30",{"name":36,"class":37},"Boehringer Ingelheim","INDUSTRY",480,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":47,"briefSummary":49,"conditions":50,"keywords":54,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100594271","NCT07017270","Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","GUARD-1","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days\n3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and\u002For insulin.\n4. Ability to provided informed consent or through their substitute decision maker\n\nExclusion Criteria:\n\n1. Type 1 DM\n2. Use of a GLP-1-RA within 30 days prior to screening\n3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)\n4. Confirmed pregnancy, women of childbearing potential\n5. Known hypersensitivity to GLP-1-RA\n6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months\n7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA",{"count":46,"type":19},100,[48],"PHASE4","This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.",[25,51,52,53],"Diabetes","Dialysis","End Stage Kidney Disease (ESRD)",[52,55,56,57,58,59],"Type 2 diabetes","semaglutide","end stage kidney disease","GLP1","GLP1RA","2026-06-22",{"date":62,"type":30},"2026-06-26",{"date":64,"type":30},"2025-11-27",{"date":66,"type":19},"2027-09",{"name":68,"class":69},"Unity Health Toronto","OTHER",2,{"id":72,"slug":4,"hasResults":10,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":20,"phases":78,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100636992","NCT07572890","Adia Med of Winter Park LLC Chronic Kidney Disease Research Study","Inclusion Criteria:\n\n* Age 18-80 years\n* Confirmed CKD diagnosis (eGFR 15-89 mL\u002Fmin\u002F1.73 m²)\n* Willingness to consider experimental treatments and comply with study requirements\n* Ability to obtain required bloodwork\n* Ability to attend all scheduled visits\n* Able to meet study cost requirements ($15,000 study fee) as described in the informed consent\n\nExclusion Criteria:\n\n* Has\n* Severe allergies to study products\n* Significant uncontrolled medical conditions\n* Immunocompromised\n* Malignancy history\n* Unstable medication regimen or inconsistent medication adherence (e.g., frequent medication changes or missed doses) within 30 days prior to Baseline, at Investigator discretion\n* Current dialysis (hemodialysis or peritoneal dialysis) or planned initiation of dialysis during the study period\n* Pregnancy or breastfeeding (if applicable)\n* Participation in another interventional trial within 30 days\n* Has had Kidney transplant\n* Prior stem cell or glutathione therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) or glutathione therapy (intravenous or topical) at any time prior to screening","80 Years",{"count":46,"type":19},[79],"PHASE1","The goal of this clinical trial is to learn whether a new regenerative treatment called AdiaVita, made from umbilical cord blood-derived stem cells and exosomes combined with glutathione, is safe and can help improve kidney function in adults with chronic kidney disease (CKD). In this condition, the kidneys gradually lose their ability to filter blood as well as they should. The main questions it aims to answer are whether AdiaVita plus glutathione improves kidney function better than control treatments, as measured by blood tests for estimated glomerular filtration rate (eGFR) and creatinine levels, and whether the treatment is safe with acceptable side effects. Researchers will compare three groups. One group will receive AdiaVita plus glutathione. A second group will receive glutathione plus a placebo for AdiaVita. The third group will receive placebos for both treatments. A placebo looks like the real treatment but contains no active ingredients. This will help determine if the full treatment works better than the controls. Approximately 100 adults aged 18 to 80 with stage 2 to 4 chronic kidney disease may participate. Participants will be randomly assigned to one of the three treatment groups. They will receive monthly intravenous infusions at the clinic for the first three months and apply a skin spray twice daily at home during that period. The study lasts 12 months total for each participant, with regular visits for blood tests, physical exams, and safety monitoring. Certain participants in the control groups may switch to the active AdiaVita treatment after three months if they meet safety criteria. This is a single-blind study, meaning participants will not know which treatment they receive. Participant safety is closely monitored by the research team and an independent board throughout the study.",[82,83,25,84,85],"Chronic Kidney Disease","Kidney Disease","Chronic Kidney Disease (CKD)","CKD",[87,88,89,90,82,85,91,92,93],"allogeneic stem cells","antioxidant therapy","stem cell therapy","stem cells","Regenerative medicine","Glutathione","Glutathione therapy","2026-06-16",{"date":96,"type":30},"2026-06-17",{"date":98,"type":19},"2026-05-18",{"date":100,"type":19},"2029-01",{"name":102,"class":69},"Adia Med of Winter Park LLC",1,{"id":105,"slug":4,"hasResults":10,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":111,"targetDuration":4,"studyType":20,"phases":113,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":70},"100530107","NCT06182475","Development and Test of a Communication Skills Training for Transplant Providers - Aims 2 & 3","Increasing Equity in Live Donor Kidney Transplantation Through Effective Patient-Provider Communication","EPPComm","Inclusion Criteria:\n\n* (1) appear for a kidney transplant evaluation at Cooperman Barnabas Medical Center (CBMC) or Temple University Hospital (TUH)\n* (2) speak English\n* (3) be of self-reported Black or Caucasian ethnicity\n* (4) be ≥18 years of age.\n\nIncluding patients who:\n\n1. have received prior kidney transplants\n2. patients with limited English proficiency, as long as they speak with the physician via a translator\n3. patients evaluated at offsite satellite locations that are not actually at CBMC or TUHS.\n\nAll transplant nephrologists, nurses, and social workers employed at the kidney transplant programs at CBMC and TUH who are actively involved in patient evaluations for transplant will be eligible for participation in the study. Providers refusing to permit digital audio recording of the transplant consultation will be deemed ineligible.\n\nExclusion Criteria:\n\n* (1) are non-verbal or otherwise unable to converse with providers\n* (2) are already listed for kidney transplant at CBMC or TUHS or at another transplant center\n* (3) have limited English proficiency and speak directly with the physician in a language other than English.\n\nPatients having (1) received an offer to donate a kidney from a family member or friend, or (2) explicitly asked a family member or friend to consider serving as a LD will be excluded, along with any patients refusing to permit digital audio recording of the transplant consultation will also be deemed ineligible to participate.\n\nThe following special populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), prisoners, and individuals who do not understand English.\n\nIt is unlikely that any female patient will be pregnant while awaiting kidney transplant; however, we will not exclude pregnant women.",{"count":112,"type":19},70,[114],"NA","The goal of this clinical trial is to understand the communication occurring between Black and Caucasian patients and their transplant providers during transplant evaluation consultations and assess relationships between these communicative elements and patient and provider factors, patient-reported outcomes and living donor transplant outcomes - living donor referrals, evaluations, and transplants. We will use these findings to inform the development of a communication skills training for transplant providers and test the impact of the training on providers' communication about live donor kidney transplants with Black and Caucasian patients and living donor transplant outcomes.\n\nThe main questions it aims to answer are:\n\n* How does the use of the use of instrumental, relational and affective communication by patients and providers during the transplant consultation differ by patient and provider factors, patient-reported outcomes and patient ethnicity?\n* What elements of instrumental, relational and affective communication will be predictive of live donor kidney transplant (LDKT) process outcomes (LD inquiries and evaluations, and actual LDKTs)?\n\nParticipants will be asked to complete brief surveys before and after the transplant consultation and to give permission for the consultation to be audiorecorded.\n\nThis data will be used to develop a training to educate providers on the key communication factors predictive of LDKT process outcomes specific to Black and Caucasian patients, and provide guidance on their application during patient consultations. Researchers will then compare communication and patient-reported and LDKT process outcomes between trained and untrained providers to see whether the training has any effect on living donor inquiries and evaluations, and actual LDKTs.",[25,117,118],"End Stage Renal Disease","Kidney Replacement",[120,121,122,123],"Patient-Provider Communication","Live Donor Kideny Transplantation","Provider Training","Communication Skills Training","NOT_YET_RECRUITING","2026-06-10",{"date":127,"type":30},"2026-06-12",{"date":129,"type":19},"2026-09",{"date":131,"type":19},"2027-05",{"name":133,"class":69},"Temple University",{"id":135,"slug":4,"hasResults":10,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":10,"sex":140,"minAge":16,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":20,"phases":144,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":103},"100458439","NCT05249634","Testosterone Treatment in Men With Chronic Kidney Disease","Effect of JATENZO® Therapy on Testosterone and Hemoglobin Concentrations in Hypogonadal Men With Chronic Kidney Disease","Inclusion Criteria:\n\n* Men between ages of 18-85 years of age\n* eGFR 15-45 ml\u002Fmin\u002F1.73m2 by MDRD (Modification of Diet in Renal Disease) equation\n* Subnormal total serum T concentrations (\\\u003C300 ng\u002Fdl) on two separate occasions in morning\n* Symptoms of hypogonadism (as per Endocrine Society guidelines): low libido, erectile dysfunction, fatigue, irritability, depressed mood, poor concentration, increased body fat, decreased muscle bulk, reduced physical performance, sleep disturbance, loss of body hair (15)\n* Normal iron stores as defined by serum ferritin ≥100 ng\u002FmL and transferrin saturation (TSAT) ≥20%.\n\nExclusion Criteria:\n\n* Use of TRT currently or in the past 6 months, including use of over-the-counter androgen containing health supplements (e.g., DHEA)\n* Hematocrit \\>48% (as per Endocrine Society guidelines)(15)\n* Treatment with erythropoiesis stimulating agents (ESA)\n* Uncontrolled blood pressure (\\>180\u002F100 mm Hg)\n* Heart Failure, class III or IV\n* Myocardial infarction, stroke, or heart surgery in the past 3 months\n* Breast cancer\n* History of prostate cancer\n* Prostate specific antigen (PSA) \\>4 ng\u002Fml, unless prostate cancer has been ruled out by a urologist (documented in physician notes)\n* HIV or untreated hepatitis C\n* Untreated, severe obstructive sleep apnea\n* Initiated iron replacement in the last 3 months\n* deep venous thrombosis or pulmonary embolism in the last 3 months\n* recurrent (more than once) deep venous thrombosis or pulmonary embolism\n* use of warfarin\n* Planning to have children in the next one year","MALE","85 Years",{"count":143,"type":19},20,[145],"PHASE2","This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).",[148,25],"Hypogonadism, Male",[150,85],"testosterone","2026-04-24",{"date":153,"type":30},"2026-04-30",{"date":155,"type":30},"2022-03-15",{"date":157,"type":19},"2028-12",{"name":159,"class":69},"St. Louis University",{"id":161,"slug":4,"hasResults":10,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":167,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":103},"100609665","NCT07217535","Rutgers University Study of the Genetics of Kidney Disease","The Rutgers University Study of the Genetics of Kidney Disease","rugcc-kd","Inclusion Criteria:\n\n* age 18 years or older\n* currently living in the United States\n* able to understand and follow written instructions in English\n* have access to the internet and a computer, laptop, tablet or smart phone\n* willing to provide written informed consent for participation\n* willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home\n* willing to complete a survey with questions about health related to the study of kidney disease\n\nExclusion Criteria:\n\n* Not able to meet or fulfill any of the inclusion criter",true,{"count":169,"type":19},50000,"OBSERVATIONAL","The goal of this observational study is to learn more about how genes impact the risk of kidney disease. Anyone 18 or older living in the US is eligible, and a diagnosis of kidney disease is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.",[83,25,173,174,175,176],"Kidney Disease, End-Stage","Kidney Diseases","Kidney Diseases, Chronic","Kidney Diseases,Cystic","2026-04-23",{"date":151,"type":30},{"date":177,"type":30},{"date":181,"type":19},"2028-10-31",{"name":183,"class":69},"Rutgers, The State University of New Jersey",{"id":185,"slug":4,"hasResults":10,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":20,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":70},"100542504","NCT06343727","A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the trial\n* Male or female aged ≥18 years with CKD\n* On chronic in-center hemodialysis for \\> 3 months\n* Serum albumin \\\u003C35 g\u002FL\n* No expected change in dialysis modality or relocation outside of Winnipeg during the intervention period (12 weeks)\n\nExclusion Criteria:\n\n* Allergy to eggs\n* History of renal transplant\n* Serum albumin ≥ 35 g\u002FL\n* Bowel diseases\n* Cancer\n* Pregnancy\n* Receiving chemotherapy treatment\n* Inability to consume treatment product\n* Allergy to study treatment ingredients\n* Planning on starting an exercise program during the duration of the trial\n* Inability to obtain written informed consent",{"count":190,"type":19},54,[114],"The goal of this clinical trial is to compare protein supplements in patients with kidney failure on dialysis. The main questions it aims to answer are:\n\n* To determine whether the supplementation of egg white protein pudding in a population of individuals with kidney failure on dialysis is feasible.\n* To determine whether egg white protein pudding supplementation improves serum albumin similar to other standard nutritional supplements.\n* To determine the effects of the egg white protein pudding on frailty measures, dietary intakes and analytes in the blood. Participants will receive either the egg white pudding (experimental) or control (Ensure plus) at the end of their dialysis treatments 3-days per week for 12 weeks.",[194,195,25],"Kidney Failure","Frailty","2026-04-17",{"date":198,"type":30},"2026-04-22",{"date":200,"type":30},"2025-07-25",{"date":202,"type":19},"2026-10-01",{"name":204,"class":205},"Seven Oaks Hospital Chronic Disease Innovation Centre","NETWORK",{"id":207,"slug":4,"hasResults":10,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100629217","NCT07471802","Monitoring of the Sympathetic\u002FVagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV)","Monitoring of the Sympathetic\u002FVagal Balance Through Multiparametric Analysis of Heart Rate Variability (HRV) in Patients With Type 2 Diabetes Mellitus (Type 2 DM), With or Without Heart Failure and\u002For Chronic Kidney Disease, or Cardiomyopathy, With Heart Failure and\u002For Cardio-renal Syndrome, All Receiving Optimized Pharmacological Treatment, Including a Sodium-Glucose Co-transporter 2 Inhibitor (SGLT2i).","GLIFO-HRV","Inclusion Criteria:\n\n* Age over 18 years;\n* Signed informed consent;\n* in Sinus rhythm;\n* Patients for whom HOLTER ECG monitoring is clinically indicated, to early identify the possible onset or progression of diabetic autonomic neuropathy, or ischemic changes, or potentially arrhythmogenic electrophysiological alterations;\n* On optimized pharmacological treatment according to clinical practice, naïve to SGLT2 inhibitor therapy, prescribed according to the (1A) recommendations of the ESC 2023 guidelines.\n\nExclusion Criteria:\n\n* Patients with atrial fibrillation or other arrhythmic burden incompatible with accurate HRV analysis;\n* Pacemaker or ICD carriers;\n* Immunodeficient patients or patients at risk of developing infections.",{"count":214,"type":19},150,"The autonomic nervous system (ANS) plays a crucial role in cardiovascular regulation by modulating heart rate in response to endogenous and environmental stimuli. Heart rate variability (HRV) analysis has been widely used as a non-invasive tool to assess autonomic function and the balance between sympathetic and parasympathetic activity. Although the physiological interpretation of some HRV parameters remains debated-particularly the low-frequency (LF) spectral component as an index of sympathetic activation-HRV remains an important method for evaluating autonomic cardiovascular control.\n\nReduced HRV has been associated with adverse outcomes in several pathological conditions and physiologically declines with aging, mainly due to progressive neuronal loss at central and spinal levels. Among conditions characterized by autonomic dysfunction, cardiovascular autonomic neuropathy (CAN) represents a common complication of diabetes mellitus (DM) and metabolic syndrome. CAN, defined as impairment of autonomic control of the cardiovascular system, develops early in the disease course and is associated with increased mortality and a higher risk of cardiovascular and renal complications.\n\nSodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed as glucose-lowering agents, have demonstrated significant cardiovascular and renal protective effects beyond glycemic control. Growing evidence suggests that these drugs exert sympathoinhibitory effects that may be beneficial not only in diabetic patients but also in conditions characterized by sympathetic overactivity. Preclinical and clinical studies have shown that SGLT2i influence autonomic regulation, including sympathetic control of renal function, with reported improvements in 24-hour blood pressure regulation and HRV parameters.\n\nLarge randomized trials have further confirmed the cardioprotective effects of SGLT2i therapy. Studies such as EMBODY, EMPEROR-Reduced, and EMPEROR-Preserved have demonstrated improvements in HRV indices and significant reductions in cardiovascular death and hospitalization for heart failure, irrespective of diabetic status.\n\nDespite these findings, the mechanisms underlying these benefits remain incompletely understood. While reduced sympathetic activity has been proposed as a key mechanism, emerging evidence suggests that SGLT2i may also enhance vagal modulation. Therefore, the present study aims to investigate, in a larger population, the effects of SGLT2i therapy on sympathovagal balance using both spectral HRV parameters and additional indices, including the parasympathetic nervous system index (PNSi), sympathetic nervous system index (SNSi), and the Baevsky Stress Index.",[217,218,25,219],"Diabete Type 2","Heart Failure","Cardiorenal Syndrome","2026-03-20",{"date":222,"type":30},"2026-03-24",{"date":224,"type":19},"2026-03-25",{"date":226,"type":19},"2031-09-01",{"name":228,"class":69},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":230,"slug":4,"hasResults":10,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":70},"100579913","NCT06830473","KTRSensor Scotland Study: An Observational Study Into Predictors and Diagnosis of Kidney Transplant Rejection","KTRSensor Scotland Study: Investigating the Role of Biomarkers in Kidney Transplant Outcomes","KTRSensors","Any patient within a Scottish Transplant centre who has undergone renal transplant (+\u002F- pancreas\u002Fislet) and is due to attend routine follow-up appointments at the index centre.\n\nExclusion criteria:\n\n* no previous kidney transplant\n* patient attending follow-up at a peripheral site\n* unable to provide urine samples across the study duration","99 Years",{"count":238,"type":19},200,"An observational study capturing real world transplant patients in the post-operative setting aiming to further determine the utility of biomarkers to improve outcomes.",[241,25],"Kidney Transplant","2026-02-09",{"date":244,"type":30},"2026-02-10",{"date":246,"type":30},"2025-05-16",{"date":248,"type":19},"2028-05-13",{"name":250,"class":69},"University of Edinburgh",{"id":252,"slug":4,"hasResults":10,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":20,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":103},"100621701","NCT07374042","Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION)","Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet","KETOPROTACTION","Inclusion Criteria:\n\n* Men or women\n* Older than 18 years of age\n* Stage 4 or 5 CKD (eGFR with CKD-EPI 2009 creatinine equation \\\u003C 30 mL\u002Fmin\u002Fm2), whitout renal replacement therapy or kidney transplantation\n* Protein intake 0.6-0.8 g\u002Fkg\u002Fd (estimated with Moroni formula)\n* Social security cover\n* Written informed consent\n\nExclusion Criteria:\n\n* Hospitalization in the past 3 months\n* Corticosteroids (\\> 7.5 mg\u002Fd), cytotoxic or immunosuppressive drugs\n* Severe symptomatic heart (NYHA 3 or 4) or liver failure (Child Pugh B or C)\n* Respiratory failure requiring oxygenotherapy\n* Ongoing infection, autoimmune disease or cancer\n* Pregnant (e.g., positive human chorionic gonadotrophin \\[HCG\\] test) or lactating patients\n* Risk of pregnancy: any woman who does not fulfil one of the following criteria:\n\n  * post-menopausal (aged \\> 45 years with amenorrhea for more than 2 years, or of any age with amenorrhea for more than 6 months and an FSH level \\> 40 mUI \u002F mL)\n  * permanent sterilisation (e.g., occlusion\u002Fbilateral ligature of the fallopian tubes, hysterectomy, bilateral salpingectomy, bilateral ovariectomy) or constitutional sterility\n  * of childbearing age and using an efficient method of contraception, begun at least 28 days before inclusion. Efficient contraception methods are: oral, injectable or implantable hormonal methods intra-uterine devices sterilisation of the male partner if he is the sole partner abstinence, if compatible with the preferred and usual lifestyle of the individual NB: if child bearing potential changes during the study, the woman must start taking one of the efficient methods of contraception as described above.\n* Patients with psychiatric or cognitive disorders rendering them unable to give written informed consent\n* Patients unwilling to participate in the study\n* Hypersensitivity to the active substances in Ketosteril®\n* Hypercalcaemia\n* Hypophosphatemia\n* Patient under a legal protection (curatorship or tutorship)","100 Years",{"count":46,"type":19},[22],"Chronic kidney disease (CKD) complicates many pathologies and the rapid increase in its prevalence constitutes a major public health concern. Whatever the cause of kidney failure, high protein consumption is a factor of progression to end-stage kidney disease. A low-protein (0.6 g\u002Fkg\u002Fd) or a very low-protein (0.3 g\u002Fkg\u002Fd) diet associated with supplementation with amino acids and\u002For keto acid analogues (KA) slows down renal function deterioration and prolongs the time before dialysis start. Difficulties in strict protein restriction implementation limit its use to a minority of CKD patients and are difficult to implement in real life.\n\nRecently KDOQI guidelines have recommended a dietary protein intake of 0.55 to 0.6 g\u002Fkg\u002Fd in CKD 3 to 5 non-diabetic patients \"metabolically stable\" and 0.6 to 0.8 g\u002Fkg\u002Fd in diabetic patients. However, the International Society of Renal Nutrition and Metabolism and the French guidelines about management of CKD propose to maintain a protein intake between 0.6 and 0.8 g\u002Fkg\u002Fd for all patients and as near as possible to 0.6 g\u002Fkg\u002Fd. This is because for a population, a mean value of 0.66 g\u002Fkg\u002Fd insures that 95% of patients are above 0.55 g\u002Fkg\u002Fd (the minimum requirement to avoid a negative nitrogen balance).\n\nExperimental studies and few clinical studies suggest a protective effect of KA supplementation on uremic sarcopenia. Interestingly this effect is also observed in patients with a protein intake of 0.6 to 0.8 g\u002Fkg\u002Fd and with a dose of KA reduced by half compared to the dose used with VLPD. Moreover, in a preliminary study, we found a nephroprotective effect of KA (1 tablet\u002F5kg body weight) in patients with an average dietary protein intake of 0.7 g\u002Fkg\u002Fd suggesting a specific effect of KA beyond protein restriction.\n\nThe hypothesis is therefore that KA treatment (1 tablet\u002F10kg), together with a dietary protein intake between 0.6 and 0.8g\u002Fkg\u002Fd, prevent muscle mass loss in patients with stages 4 and 5 CKD. If these results were confirmed, this could expand the population that could benefit from KA supplementation.",[25],"2026-01-20",{"date":265,"type":30},"2026-01-28",{"date":267,"type":30},"2026-01-05",{"date":269,"type":19},"2030-01",{"name":271,"class":69},"University Hospital, Clermont-Ferrand",{"id":273,"slug":4,"hasResults":10,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":20,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100611469","NCT07240987","Mesenchymal Stem Cells for Chronic Kidney Diseases","A Randomized Controlled Study of Mesenchymal Stem Cells in the Treatment of Chronic Kidney Diseases","Inclusion Criteria:\n\n* Agreement to participate in the trial and provision of signed written informed consent\n* Pathological diagnosis of diabetic nephropathy or hypertensive renal damage\n* 15 ≤ eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m², UACR \\> 300 mg\u002Fg\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Extremely severe anemia (hemoglobin \\\u003C 30 g\u002FL)\n* Received blood product transfusion therapy within 1 month\n* Autosomal dominant or recessive polycystic kidney disease (ADPKD)\n* History of kidney transplant or other solid organ transplant\n* Active systemic or localized infection (e.g., pneumonia, osteomyelitis)\n* Allergy to stem cells themselves or stem cell-related culture medium\n* History of allergic reaction to cell products (e.g., blood transfusion, platelets)\n* History of coagulation disorders (thromboembolism, pulmonary embolism, deep vein thrombosis)\n* History of malignancy or current malignant disease\n* Elevated tumor markers (AFP, CEA, CA199, CA125, etc.)\n* Pregnant women or women with plans for pregnancy within 3 months after MSC therapy\n* Participation in drug-related clinical trials within the past 2 months\n* Any form of drug abuse, mental illness, or other conditions considered by the investigator as potentially affecting the trial's validity or the subject's health",{"count":279,"type":19},32,[79,145],"This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.",[25,283,284],"Diabetic Kidney Disease (DKD)","Hypertensive Nephropathy","2025-12-18",{"date":287,"type":30},"2025-12-24",{"date":289,"type":19},"2026-01-01",{"date":291,"type":19},"2027-08-31",{"name":293,"class":69},"The First Affiliated Hospital of Air Force Medicial University",{"id":295,"slug":4,"hasResults":10,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":20,"phases":303,"briefSummary":304,"conditions":305,"keywords":308,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":103},"100570021","NCT06701825","Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus","A Multicentre, Controlled, Randomised and Single-blind, Adaptive Phase IV Protocol to Evaluate Effectiveness and Cost-effectiveness of Pre-emptive Genotyping Strategy to Optimise Tacrolimus Dosage in a Pretransplant Chronic Kidney Disease Population Cohort","TRANSPGx","Inclusion Criteria:\n\n1. Participants must be willing and able to provide written informed consent prior the initiation of any study procedures.\n2. Subject or their legally authorized representative has voluntarily signed the informed consent document.\n3. Participant is on the waiting list for a kidney transplant.\n4. Subject is able and willing to take part and be followed-up for the majority of the study duration, and adhere to the procedures specified in this protocol.\n5. Subjects must be naïve to any genotyping test of the following genes: CYP3A5.\n\nExclusion Criteria:\n\n1. Known hypersensitivity\u002Fallergy reaction to tacrolimus or any of the excipients.\n2. History of renal, heart, and\u002For liver transplant.\n3. History or clinical evidence of any disease and\u002For existence of any surgical or medical condition, which might interfere in a relevant manner with the absorption, distribution, metabolism, or excretion of the study treatment, except for renal disease.\n4. Any condition or situation precluding or interfering the compliance with the protocol.\n5. Any condition at medical discretion for which renal transplantation and\u002For study treatment should not be received.",{"count":302,"type":19},114,[48],"This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective, cost-effective, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol.",[25,306,307],"Transplant Recipient (Kidney)","Immunosuppression",[309,310,311,312,313],"Tacrolimus","Kidney transplant","Cost-effectiveness","Pharmacogenetic","Phase IV Clinical Trial","2025-09-04",{"date":316,"type":30},"2025-09-11",{"date":318,"type":30},"2025-06-02",{"date":320,"type":19},"2026-12-31",{"name":322,"class":69},"Instituto de Investigación Hospital Universitario La Paz",{"id":324,"slug":4,"hasResults":10,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":167,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":20,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":103},"100580775","NCT06841692","Diuretic Testing in Chronic Kidney Disease","U-TUBE 2","Inclusion Criteria for CKD subjects:\n\n* CKD stage G3 (creatinine-based eGFR 30-59 mL\u002Fmin\u002F1.73m2) during the last outpatient visit\n\nInclusion Criteria for Healthy subjects:\n\n• eGFR within the expected range for age (a decline of 1 ml\u002Fmin\u002F1.73 m2 per year starting from age 40 is considered the normal age-related decline in kidney function\n\nExclusion Criteria:\n\n* Known intolerance or allergy to the diuretics\n* Current systemic chemotherapy for malignancy\n* Kidney transplant recipient\n* Use of calcineurin-inhibitors\n* Life expectancy \\\u003C 12 months\n* Current immunosuppressive treatment for glomerulonephritis\n* Incapacitated subjects or subjects who are deemed unfit to adequately adhere to instructions from the research team\n* Hypokalemia or hyperkalemia (K+ \\\u003C 3.0mmol\u002FL or K+ \\> 5.5 mmol\u002FL) at inclusion visit\n* Hypo- or hypernatremia (Na+ \\\u003C 130 mmol\u002FL or Na+ \\> 150mmol\u002FL) at inclusion visit\n* Inherited tubulopathy as the cause of CKD\n* Autosomal dominant polycystic or tubulointerstitial kidney disease causing CKD\n* Clinically relevant heart failure (New York Heart Association class III or IV)\n* Therapy-resistant hypertension, defined as systolic blood pressure \\> 180mmHg at the inclusion visit\n* Current treatment with inhibitors of Organic anion transporters: probenecid, pravastatin, cimetidine, cephalosporins, acetazolamide \\[22\\]\n* Active hepatitis during last outpatient visit\n* Liver cirrhosis in advanced stage (Child-Pugh B or C)\n* Active drug- or alcohol abuse\n* Not being able to tolerate a 28-day washout of one of the drugs interfering with diuretic testing.\n* Women who are pregnant, breastfeeding, or planning on becoming pregnant before the test day",{"count":330,"type":19},86,[114],"The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are:\n\nDoes a worse result of a diuretic test predict the progression of chronic kidney disease?\n\nIf there is a comparison group: Researchers will compare the diuretic test in patients with chronic kidney disease to healthy participants to see if the results are different in a healthy kidney.\n\nParticipants will undergo diuretic testing. This involves the administration of bumetanide and hydrochlorothiazide with subsequent blood and urine collections.",[25],[335,336,82,337],"Disease Progression","Diuretic Testing","Kidney Tubular Function","2025-08-06",{"date":340,"type":30},"2025-08-07",{"date":342,"type":30},"2025-04-01",{"date":344,"type":19},"2029-10-31",{"name":346,"class":69},"Erasmus Medical Center",{"id":348,"slug":4,"hasResults":10,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":20,"phases":356,"briefSummary":357,"conditions":358,"keywords":362,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":103},"100582429","NCT06863194","Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial","Effects of Probiotic Supplementation on Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease: A Randomized Controlled Trial","PRO-CKD","Inclusion Criteria:\n\n* Adults aged ≥ 18 years (both males and females).\n* Diagnosed with Chronic Kidney Disease (CKD) Stage III or IV, confirmed by eGFR.\n* Stable medical condition with no recent hospitalization for acute kidney injury or other serious illnesses.\n* Not currently on probiotic supplementation or prebiotic therapy.\n* Willing to provide informed consent and comply with the study protocol, including clinic visits and sample collection.\n\nExclusion Criteria:\n\n* CKD Stage I, II, or V, or on dialysis.\n* Currently using probiotics or prebiotics as part of their diet or treatment.\n* History of active malignancy (cancer) or undergoing chemotherapy.\n* Significant gastrointestinal disease (e.g., inflammatory bowel disease, irritable bowel syndrome, or recent GI surgery).\n* Pregnant or breastfeeding women (due to safety concerns).\n* Patients with autoimmune diseases (e.g., lupus, rheumatoid arthritis).\n* Individuals on long-term antibiotic or anti-inflammatory medication that could interfere with microbiota composition.\n* Individuals with severe behavioral or cognitive disorders that may prevent adherence to the study protocol.",{"count":355,"type":19},72,[79,145],"The goal of this clinical trial is to learn whether probiotic supplementation can slow disease progression in patients with moderate to severe chronic kidney disease (CKD). The trial will also assess the safety of probiotics in these patients.\n\nThe main questions the study aims to answer are:\n\nDoes probiotic supplementation improve kidney function by reducing serum creatinine levels and protein in urine? Does it reduce inflammation and metabolic imbalances in CKD patients? Does it affect gut microbiota composition and lower harmful toxins in the body? Is probiotic supplementation safe and well-tolerated in CKD patients?\n\nParticipants will:\n\nBe randomly assigned to receive either probiotics or a placebo for 6 months. Have clinic visits every 6 months for checkups, blood tests, and urine tests. Be monitored for any side effects and changes in kidney function. Researchers will compare the probiotic group to the placebo group to determine whether probiotics are effective in slowing CKD progression.",[25,359,360,361],"Renal Insufficiency, Chronic","Gut Dysbiosis","Uremic Toxins",[84,363,364,361,365,366,367,368],"Probiotics","Gut Microbiota","Indoxyl Sulfate (IS)","Inflammation in CKD","Dysbiosis in CKD","Lactobacillus plantarum","2025-05-13",{"date":246,"type":30},{"date":372,"type":30},"2025-04-03",{"date":374,"type":19},"2025-10-20",{"name":376,"class":69},"Mansoura University",{"id":378,"slug":4,"hasResults":10,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":20,"phases":384,"briefSummary":385,"conditions":386,"keywords":387,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":103},"100580922","NCT06843603","Barriers\u002FFacilitators and Care Coordination of Native Hawaiians & Kidney Disease","AIM 1 and AIM 2: Inclusion Criteria: Native Hawaiian (NH) participants from the NKFH KEDS program are:\n\n* greater or equal to 18 years\n* self-reported as Native Hawaiian\n* eGFR less than 60 ml\u002Fmin\u002F1.73m2 (Stage 3a-3b CKD) and\u002For greater or equal to 30 mg\u002Fg UACR\n* have participated in the NKFH KEDS Program within 3 months\n* able to read, write, and speak English.\n\nAIM 1 and AIM 2: Inclusion Criteria: NKFH and PCP staff are :\n\n* able to read, write, and speak English,\n* greater or equal to 18 years.\n\nExclusion Criteria: None",{"count":383,"type":19},120,[114],"Native Hawaiians (NH) are 9.5 times more likely to be on dialysis or need a kidney transplant compared to Whites. They have the highest end-stage kidney disease (ESKD) incidence rates in the nation, begin dialysis at younger ages (30-50 years), and one of the most under-studied racial\u002Fethnic groups in chronic kidney disease (CKD) research. This project's outcome is to improve kidney disease follow-up among early stage NHs at high risk by aligning health equity with a culturally appropriate care coordination systems model.",[25],[388],"kidney disease, chronic","2025-02-18",{"date":391,"type":30},"2025-02-25",{"date":393,"type":19},"2025-09-01",{"date":291,"type":19},{"name":396,"class":69},"University of Hawaii",{"id":398,"slug":4,"hasResults":10,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":20,"phases":405,"briefSummary":406,"conditions":407,"keywords":410,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":103},"100569283","NCT06692231","Impact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients","Impact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients After Assessment of Health Literacy Level","IPhaDia","Inclusion Criteria:\n\n* Patient over 18 years of age\n* On dialysis (peritoneal dialysis, hemodialysis) for at least 3 months\n* Prescription for at least 5 daily medications\n* Patient who has not received any pharmaceutical consultation from a hospital pharmacist as part of his or her treatment for chronic renal failure.\n\nExclusion Criteria:\n\n* Patient does not speak and\u002For understand French\n* Patient's cognitive state does not permit an interview\n* Patient not autonomous in managing his or her daily medication (e.g.: patient in nursing home)\n* Patient refusal",{"count":112,"type":19},[114],"The goal of this clinical trial is to learn if an intervention of a hospital pharmacist could help, dialysis patients managed his treatment. In a first time, the health literacy level will be assed.\n\nThe main questions it aims to answer are:\n\nWhat is the impact of the clinical pharmacist intervention on the understanding level and management level of his treatment by the patient? Does the intervention of the pharmacist has an effect on the biologicals parameters of the patient? Researchers will compare a group with a pharmacist intervention VS a group without pharmacist intervention for dialysis patients.",[408,409,25],"Renal Dialysis","Health Literacy Level",[411,412],"clinical pharmacist","end stage renal disease","2024-11-14",{"date":415,"type":30},"2024-11-18",{"date":417,"type":19},"2024-11-15",{"date":419,"type":19},"2027-02-28",{"name":421,"class":69},"Centre Hospitalier de Vichy",{"id":423,"slug":4,"hasResults":10,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":10,"sex":140,"minAge":429,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":20,"phases":433,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":103},"100558747","NCT06555146","Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy","Glucagon-like Peptide-1's Effect on Renal Regional Blood Flow and the Renal Function in Patients With Type 2 Diabetes Mellitus","Sema-RMA","Inclusion Criteria:\n\n* Type 2 diabetes mellitus diagnosed through either HbA1c ≥6,5% but ≤8,5%, or \\\u003C6,5% combined with either fasting plasma glucose ≥7,0 mmol\u002FL or plasma glucose ≥11,1 mmol\u002FL two hours after an oral glucose tolerance test (OGTT).\n* Estimated glomerular filtration rate (eGFR, CKD-EPI) between 30-60 mL\u002Fmin\u002F1.73m2\n* Urine Albumin:Creatinine ratio (UACR) ≥30mg\u002Fg\n* Stable RAAS blockade (ACE inhibitors or angiotensin II receptor blocker (ARB) with stable dosis for 4 weeks prior to screening)\n* Discontinuation of treatment with selective sodium glucose transporter inhibitors (SGLT2i), dipeptidyl peptidase 4 inhibitors (DPP-4i), GLP-1R analogs, rapid-acting and mix insulin 30 days before screening.\n\nExclusion Criteria:\n\n* Immunosuppressive therapy within 30 days of screening\n* Alcohol abuse\n* Medical treatment with glucocorticoids\n* Kidney transplantation\n* Treatment for renal failure with dialysis\n* Myocardial infarction within 3 months of screening\n* Heart failure (NYHA 3-4)\n* Dysregulated arterial hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥ 100 mm Hg)\n* Liver disease (ALAT \\>2 x normal value)\n* Conditions which may interfere with the glucose metabolism according to the PI\n* Severe claustrophobia\n* Elements incompatible with MRI\n* Abnormal kidney size and\u002For position\n* Venous and arterial anatomy hindering catheterization.","20 Years","60 Years",{"count":432,"type":19},15,[114],"The goal of this double-blinded, placebo-controlled, randomized, crossover study is to examine the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on renal hemodynamics and function in patients with type 2 diabetes mellitus (T2DM) and moderate chronic kidney disease (CKD).\n\nThe study will determine the effects of semaglutide on:\n\n* Renal arterial blood flow, regional renal perfusion, and oxygenation\n* Activity of the renin-angiotensin-aldosterone system (RAAS)\n* The glomerular filtration rate (GFR)\n* Sodium excretion in urine\n* Blood pressure and heart rate",[436,25],"Diabetes Mellitus, Type 2",[438,439,440,441,442],"Renal flow","Regional renal perfusion","Sodium excretion in urine","Renin angiotensin aldosterone system","Glomerular filtration rate","2024-08-12",{"date":445,"type":30},"2024-08-15",{"date":447,"type":19},"2024-08",{"date":449,"type":19},"2025-03",{"name":451,"class":69},"Bispebjerg Hospital",{"id":453,"slug":4,"hasResults":10,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":460,"conditions":461,"keywords":468,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":103},"100458345","NCT05248412","The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases","The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of Patients With Non-communicable Diseases (and Without COVID-19) : an In-depth Outcome and Health Economic Evaluation","(For cohort study)\n\nInclusion Criteria:\n\n* People aged 18 years or above with a documented doctor-diagnosed NCDs (diabetes mellitus, hypertension, cardiovascular disease, cancer, chronic kidney disease, or chronic respiratory disease )\n* People who attended at least once HA hospitals, general or specialist out-patients clinics between 1 January 2010 and 31 December 2024\n\nExclusion Criteria:\n\n\\- People with a documented doctor-diagnosed COVID-19\n\n(For cross-sectional study)\n\nInclusion Criteria:\n\n* People aged 18 years or above with a documented doctor-diagnosed NCDs (diabetes mellitus, hypertension, cardiovascular disease, cancer, chronic kidney disease, or chronic respiratory disease )\n* All participants are able to communicate in either Chinese or English and provide informed consent.\n\nExclusion Criteria:\n\n* People with a documented diagnosis of COVID-19 during the study period.",{"count":459,"type":19},250000,"Objectives and aim: To evaluate the long-term spill-over (indirect) effect of Coronavirus disease (COVID-19) on health outcomes and healthcare utilization among people with non-communicable diseases and without COVID-19.\n\nDesign: A population-based cohort study using electronic health records of the Hospital Authority (HA) clinical management system, economic modeling, and serial cross-sectional surveys on healthcare service utilization.\n\nSetting: HA public hospitals and outpatient clinics in Hong Kong\n\nParticipants: People aged ≥ 18 years with a documented diagnosis of diabetes mellitus, hypertension, cardiovascular disease, cancer, chronic respiratory disease, and chronic kidney disease; without COVID-19; attending HA services between 2010 and 2024.\n\nMain outcome measures: All-cause mortality, disease-specific outcomes, healthcare service utilization, and costs.\n\nMethods: The annual incidence of each outcome in each year between 2010 and 2024 will be calculated. An interrupted time-series analysis to assess the changes in outcomes between pre-and-post-COVID-19 outbreak periods. Long term health economic impact of healthcare disruptions during the COVID-19 outbreak will be modeled using microsimulation. Multivariable Cox proportional hazards regression and Poisson\u002Fnegative binomial regression to evaluate the effect of different modes of care on the risk of the outcomes.\n\nImplications: Findings will inform policies and practices on contingency care plans to avoid excessive morbidity and mortality and to assure the quality of care for patients with NCD as part of the territorial response to the health crisis.",[462,463,464,465,466,25,467],"Diabetes Mellitus","Hypertension","Cancer","Cardiovascular Diseases","Chronic Respiratory Disease","Noncommunicable Diseases",[469,470,471,472,467],"COVID-19 Pandemic","Morality","Complication","Utilization, Health Care","2022-02-20",{"date":475,"type":30},"2022-03-08",{"date":477,"type":30},"2021-06-21",{"date":479,"type":19},"2026-06-30",{"name":481,"class":69},"The University of Hong Kong",""]